Isabelle Opitz

Prof. Dr. Isabelle Opitz

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 October 2022 in European Respiratory Journal
Verified
Journal Article
Closed access
PDF file
EBEihab O Bedawi
Eihab O Bedawi
Sara RicciardiSara Ricciardi
Sara Ricciardi
MHMaged Hassan
Maged Hassan
MGMichael R. Gooseman
Michael R. Gooseman
RARachelle Asciak
Rachelle Asciak
NRNajib Rahman
Najib Rahman
Objective Vulvar squamous cell carcinoma and in situ lesions can be stratified by human papillomavirus (HPV) and TP53 status into prognostic risk groups using p16 and p53 immunohistochemistry. We assessed the significance of vulvar squamous cell carcinoma resection margin positivity for either differentiated vulvar intra-epithelial neoplasia (dVIN) or abnormal p53 immunohistochemistry, and other pathologic variables, in a cohort of patients with HPV-independent (HPV-I) p53 abnormal (p53abn) vulvar squamous cell carcinomas. Methods Patients with stage I–II HPV-I p53abn vulvar squamous cell carcinoma with negative invasive margins who did not receive adjuvant radiation from a single institution were included. Tumors underwent margin reassessment using p53 immunohistochemistry. Cases were segregated into (1) morphologic dVIN at margin; or (2) abnormal p53 immunohistochemistry staining at margin without morphologic dVIN (p53abn immunohistochemistry); or (3) margins negative by morphology and p53 immunohistochemistry. Clinicopathologic/outcome data were collected. Results A total of 51 patients were evaluated: (1) 12 with dVIN on margin; (2) 12 with p53abn immunohistochemistry on margin without morphologic dVIN; and (3) 27 with margins negative for morphologic dVIN and p53abn immunohistochemistry. The recurrence rate for patients with dVIN or p53abn immunohistochemistry on the margin was equally high at 75% each, compared with 33% with margins negative for morphologic dVIN and p53abn immunohistochemistry (p=0.009). On multivariate analysis, positive in situ margins maintained an association with disease recurrence (p=0.03) whereas invasive margin distance (radial and deep), lymphovascular invasion, and tumor size did not. Conclusions Patients with stage I–II HPV-I vulvar squamous cell carcinoma with margins positive for either dVIN or p53abn immunohistochemistry without morphologic dVIN showed increased disease recurrence, regardless of invasive margin distance. These findings show that p53 immunohistochemistry is a useful adjunct for evaluating margin status in HPV-I vulvar squamous cell carcinoma and may support repeat excision for positive in situ margins (dVIN or p53abn immunohistochemistry).

1 June 2023 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Open access
PDF file
SGSteering group
Steering group
ABAlessandro Brunelli
Alessandro Brunelli
HDHerbert Decaluwe
Herbert Decaluwe
MGMichel Gonzalez
Michel Gonzalez
DGDominique Gossot
Dominique Gossot
GVGiulia Veronesi
Giulia Veronesi
Steering group , Alessandro Brunelli, Herbert Decaluwe, Michel Gonzalez, Dominique Gossot, Rene Petersen, Expert panel , Florian Augustin, Jalal Assuad, Jean Ma

23 May 2014 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ARArun Renganathan
Arun Renganathan
JKJelena Kresoja-Rakic
Jelena Kresoja-Rakic
NENohemy Echeverry
Nohemy Echeverry
GZGabriela Ziltener
Gabriela Ziltener
BVBart Vrugt
Bart Vrugt
Emanuela Felley-BoscoEmanuela Felley-Bosco
Emanuela Felley-Bosco
Malignant pleural mesothelioma (MPM) is an aggressive cancer with short overall survival. Long non-coding RNAs (lncRNA) are a class of RNAs more than 200 nucleotides long that do not code for protein and are part of the 90% of the human genome that is transcribed. Earlier experimental studies in mice showed GAS5 (growth arrest specific transcript 5) gene deletion in asbestos driven mesothelioma. GAS5 encodes for a lncRNA whose function is not well known, but it has been shown to act as glucocorticoid receptor decoy and microRNA “sponge”. Our aim was to investigate the possible role of the GAS5 in the growth of MPM.

24 August 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SHStefanie Hiltbrunner
Stefanie Hiltbrunner
LCLena Cords
Lena Cords
SKSabrina Kasser
Sabrina Kasser
SFSandra N. Freiberger
Sandra N. Freiberger
SKSusanne Kreutzer
Susanne Kreutzer
ACAlessandra Curioni-Fontecedro
Alessandra Curioni-Fontecedro
Immune checkpoint inhibitor treatment has the potential to prolong survival in non-small cell lung cancer (NSCLC), however, some of the patients develop resistance following initial response. Here, we analyze the immune phenotype of matching tumor samples from a cohort of NSCLC patients showing good initial response to immune checkpoint inhibitors, followed by acquired resistance at later time points. By using imaging mass cytometry and whole exome and RNA sequencing, we detect two patterns of resistance¨: One group of patients is characterized by reduced numbers of tumor-infiltrating CD8+ T cells and reduced expression of PD-L1 after development of resistance, whereas the other group shows high CD8+ T cell infiltration and high expression of PD-L1 in addition to markedly elevated expression of other immune-inhibitory molecules. In two cases, we detect downregulation of type I and II IFN pathways following progression to resistance, which could lead to an impaired anti-tumor immune response. This study thus captures the development of immune checkpoint inhibitor resistance as it progresses and deepens our mechanistic understanding of immunotherapy response in NSCLC.

1 November 2018 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
RBRaphael Bueno
Raphael Bueno
IOIsabelle Opitz
Isabelle Opitz

25 May 2020 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
IOIsabelle Opitz
Isabelle Opitz
ASArnaud Scherpereel
Arnaud Scherpereel
TBThierry Berghmans
Thierry Berghmans
IPIoannis Psallidas
Ioannis Psallidas
MGMarkus Glatzer
Markus Glatzer
GCGiuseppe Cardillo
Giuseppe Cardillo
The European Respiratory Society (ERS)/European Society of Thoracic Surgeons (ESTS)/European Association for Cardio-Thoracic Surgery (EACTS)/European Society for Radiotherapy and Oncology (ESTRO) task force brought together experts to update previous 2009 ERS/ESTS guidelines on management of malignant pleural mesothelioma (MPM), a rare cancer with globally poor outcome, after a systematic review of the 2009–2018 literature. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach. The evidence syntheses were discussed and recommendations formulated by this multidisciplinary group of experts. Diagnosis: pleural biopsies remain the gold standard to confirm the diagnosis, usually obtained by thoracoscopy but occasionally via image-guided percutaneous needle biopsy in cases of pleural symphysis or poor performance status. Pathology: standard staining procedures are insufficient in ∼10% of cases, justifying the use of specific markers, including BAP-1 and CDKN2A (p16) for the separation of atypical mesothelial proliferation from MPM. Staging: in the absence of a uniform, robust and validated staging system, we advise using the most recent 2016 8th TNM (tumour, node, metastasis) classification, with an algorithm for pretherapeutic assessment. Monitoring: patient’s performance status, histological subtype and tumour volume are the main prognostic factors of clinical importance in routine MPM management. Other potential parameters should be recorded at baseline and reported in clinical trials. Treatment: (chemo)therapy has limited efficacy in MPM patients and only selected patients are candidates for radical surgery. New promising targeted therapies, immunotherapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasize that patients who are considered candidates for a multimodal approach, including radical surgery, should be treated as part of clinical trials in MPM-dedicated centres.